7. Special Populations and Emerging Topics
Pedagogy: This lesson uses indication-specificity reasoning — ensuring clinicians understand that HSDD is the ONLY evidence-based indication for testosterone and that off-label prescribing requires careful governance.
Learning Objectives
- State that HSDD in postmenopausal women is the only evidence-based indication for testosterone therapy
- Describe the transdermal route requirement and target physiological levels
- Outline monitoring: total testosterone, lipid profile, liver function
- Acknowledge the lack of government-approved female testosterone formulations outside Australia
Key Facts
Indications and Evidence
The 2019 global consensus (Davis et al.) and IMS 2025: HSDD in postmenopausal women is the only evidence-based indication. RCTs consistently show testosterone improves sexual desire, arousal, orgasm frequency, and self-image vs placebo (1,2).
Prescribing
Transdermal route ONLY. Dose: aim for premenopausal physiological testosterone levels. No government-approved formulation exists for women outside Australia. UK practice: compounded transdermal testosterone from reliable pharmacies, or off-label use of male preparations at 1/10th dose (e.g. Testogel 1% — apply pea-sized amount daily). Monitor: total testosterone at 3 months and 6-monthly (target upper half of premenopausal range); lipid profile; LFTs (1,2).
Safety
Short-term safety data (meta-analysis, 300mcg/day transdermal): common adverse effects are acne and hair growth. No alopecia, clitoromegaly, or voice deepening at physiological doses. Lipid profiles, cardiometabolic markers, liver and kidney function unchanged. Long-term data beyond 2 years are limited (2). Sublingual, intramuscular, oral, and pellet formulations are NOT recommended due to supraphysiological levels (2).
Clinical Pearl Testosterone therapy in women has ONE indication: HSDD in postmenopausal women. It is NOT indicated for fatigue, cognition, bone health, or general wellbeing — despite patient demand driven by media coverage.
Clinical Pearl There is no licensed testosterone product for women in the UK. All prescribing is off-label. Document the indication, consent, and monitoring plan clearly.
Case-Based Examples
Case 1: 54-year-old on HRT with persistent low libido
Presentation: A 54-year-old on adequate HRT (VMS controlled, GSM treated with vaginal oestrogen) reports persistent loss of sexual desire causing relationship distress. No depression (PHQ-9 normal). No medication causing sexual dysfunction.
Question: Is testosterone indicated? How would you prescribe and monitor?
Model Answer: HSDD criteria met: persistent low desire causing distress, not explained by another condition or medication, in a postmenopausal woman on adequate oestrogen. Testosterone is indicated. Prescribe: compounded transdermal testosterone cream (e.g. 5mg/ml, apply 0.5ml daily to inner thigh) or off-label Testogel 1% (pea-sized amount daily). Check baseline: total testosterone, SHBG, lipids, LFTs. Review at 3 months: symptoms, testosterone level (target upper half premenopausal range), side effects (acne, hair growth). If no benefit at 6 months on adequate levels: discontinue. Monitor 6-monthly.
Case 2: Patient requesting testosterone for 'energy and brain fog'
Presentation: A 49-year-old perimenopausal woman on sequential HRT asks for testosterone because she read it helps with fatigue and cognitive function.
Question: How do you respond?
Model Answer: Empathise with her symptoms — fatigue and brain fog are common and distressing. However: testosterone is ONLY evidence-based for HSDD. The global consensus (Davis et al., 2019) specifically states there is insufficient evidence to support testosterone for cognition, fatigue, musculoskeletal health, or general wellbeing. IMS 2025 concurs. Instead: optimise her HRT (dose adequate?), assess for other causes of fatigue (thyroid function, iron studies, sleep quality, depression), and address cognitive symptoms with reassurance (menopausal brain fog is typically self-limiting). Exercise and sleep optimisation are evidence-based for energy and cognition.
Self-Assessment Questions
PLAB/MLA Indication for testosterone in women
What is the ONLY evidence-based indication for testosterone therapy in postmenopausal women?
A. Fatigue
B. Osteoporosis prevention
C. Hypoactive sexual desire disorder (HSDD)
D. Cognitive decline
Answer: C. Global consensus (Davis et al., 2019) and IMS 2025: HSDD in postmenopausal women is the sole evidence-based indication.
MRCGP Testosterone prescribing governance
What governance considerations apply when prescribing testosterone to a woman in the UK?
A. No special considerations — it is a licensed indication
B. All prescribing is off-label; document indication, informed consent, and monitoring plan; use transdermal route only; target physiological levels
C. Testosterone cannot be prescribed by GPs
D. Only intramuscular testosterone is appropriate
Answer: B. No licensed female testosterone product exists in the UK. All prescribing is off-label. Requires clear documentation, informed consent, and structured monitoring (testosterone levels, lipids, LFTs).
Professor Long-term safety evidence gap
Evaluate the implications of the absence of long-term safety data (beyond 2 years) for testosterone therapy in women.
A. 2 years of data is sufficient for lifetime prescribing
B. The absence of long-term data means clinicians must balance demonstrated short-term benefit (RCTs up to 24 months) against unknown long-term cardiovascular and breast cancer outcomes — informed consent should explicitly address this uncertainty
C. Long-term testosterone is proven safe
D. No data exist at all
Answer: B. Meta-analyses provide reassuring short-term data (up to 24 months): no adverse cardiovascular, breast, or hepatic signals. However, androgen receptor expression in breast tissue means theoretical concern persists. The Australian prospective registry may eventually provide longer-term data. In the interim, informed consent should explicitly acknowledge the evidence gap, and periodic reassessment of the benefit-risk balance is essential.
Take-Away Messages
- HSDD in postmenopausal women is the ONLY evidence-based indication for testosterone
- Transdermal route only; aim for premenopausal physiological levels
- No licensed female testosterone product in the UK — all prescribing is off-label
- Monitor: total testosterone, lipids, LFTs at baseline, 3 months, then 6-monthly
- Long-term safety data beyond 2 years are limited — informed consent must address this